JP6667043B1 - Microemulsions and the use of microemulsions - Google Patents
Microemulsions and the use of microemulsions Download PDFInfo
- Publication number
- JP6667043B1 JP6667043B1 JP2019194591A JP2019194591A JP6667043B1 JP 6667043 B1 JP6667043 B1 JP 6667043B1 JP 2019194591 A JP2019194591 A JP 2019194591A JP 2019194591 A JP2019194591 A JP 2019194591A JP 6667043 B1 JP6667043 B1 JP 6667043B1
- Authority
- JP
- Japan
- Prior art keywords
- oil
- poorly water
- microemulsion
- soluble functional
- functional component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004530 micro-emulsion Substances 0.000 title claims abstract description 116
- 239000002245 particle Substances 0.000 claims abstract description 105
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 238000009826 distribution Methods 0.000 claims abstract description 21
- 239000003921 oil Substances 0.000 claims description 124
- 239000004094 surface-active agent Substances 0.000 claims description 60
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 47
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 47
- 229920000053 polysorbate 80 Polymers 0.000 claims description 47
- 229940068968 polysorbate 80 Drugs 0.000 claims description 47
- 239000004359 castor oil Substances 0.000 claims description 39
- 235000019438 castor oil Nutrition 0.000 claims description 39
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 39
- -1 polyoxyethylene Polymers 0.000 claims description 39
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 37
- 239000012736 aqueous medium Substances 0.000 claims description 25
- 235000013376 functional food Nutrition 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 239000002917 insecticide Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 238000010586 diagram Methods 0.000 abstract description 2
- 235000019198 oils Nutrition 0.000 description 121
- 238000002156 mixing Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000000126 substance Substances 0.000 description 17
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 9
- 235000012424 soybean oil Nutrition 0.000 description 9
- 239000003549 soybean oil Substances 0.000 description 9
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 235000019864 coconut oil Nutrition 0.000 description 8
- 239000003240 coconut oil Substances 0.000 description 8
- 235000017471 coenzyme Q10 Nutrition 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 6
- 235000012754 curcumin Nutrition 0.000 description 6
- 239000004148 curcumin Substances 0.000 description 6
- 229940109262 curcumin Drugs 0.000 description 6
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 229960005375 lutein Drugs 0.000 description 6
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 4
- 235000019489 Almond oil Nutrition 0.000 description 4
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 4
- 239000008168 almond oil Substances 0.000 description 4
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000010667 rosehip oil Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 3
- 239000004212 Cryptoxanthin Substances 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 3
- 239000011795 alpha-carotene Substances 0.000 description 3
- 235000003903 alpha-carotene Nutrition 0.000 description 3
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 3
- 235000013793 astaxanthin Nutrition 0.000 description 3
- 239000001168 astaxanthin Substances 0.000 description 3
- 229940022405 astaxanthin Drugs 0.000 description 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 3
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- 235000019244 cryptoxanthin Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 3
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 235000012680 lutein Nutrition 0.000 description 3
- 239000001656 lutein Substances 0.000 description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 3
- 235000012661 lycopene Nutrition 0.000 description 3
- 239000001751 lycopene Substances 0.000 description 3
- 229960004999 lycopene Drugs 0.000 description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000010466 nut oil Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229930003802 tocotrienol Natural products 0.000 description 3
- 239000011731 tocotrienol Substances 0.000 description 3
- 235000019148 tocotrienols Nutrition 0.000 description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000008210 xanthophylls Nutrition 0.000 description 3
- 235000010930 zeaxanthin Nutrition 0.000 description 3
- 239000001775 zeaxanthin Substances 0.000 description 3
- 229940043269 zeaxanthin Drugs 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000003447 Pistacia vera Nutrition 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000005658 Tebufenpyrad Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000012644 addition polymerization Methods 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 239000006103 coloring component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 description 1
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229940063845 saw palmetto extract Drugs 0.000 description 1
- 239000010018 saw palmetto extract Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- ZZYSLNWGKKDOML-UHFFFAOYSA-N tebufenpyrad Chemical compound CCC1=NN(C)C(C(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1Cl ZZYSLNWGKKDOML-UHFFFAOYSA-N 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000010913 used oil Substances 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
Abstract
【課題】乳剤化した粒子の粒子径が小さく、粒子径分布が狭く、且つ、粒子径の均質性が向上しているとともに、安定性に優れたマイクロエマルション、かかるマイクロエマルションを調製するための組成物、これらの製造方法、及びマイクロエマルションの利用物を提供する。【解決手段】平均粒子径が１８ｎｍ以下であり、粒度分布指標が０．１４以下であり、且つ、１００ｎｍ以上の粒子を含まない単一分散の、マイクロエマルションを調製する。【選択図】なしPROBLEM TO BE SOLVED: To obtain a microemulsion having a small particle size of emulsified particles, a narrow particle size distribution, improved homogeneity of particle size, and excellent stability, and a composition for preparing such a microemulsion. The present invention provides a product, a method for producing the same, and a use product of a microemulsion. A monodisperse microemulsion having an average particle size of 18 nm or less, a particle size distribution index of 0.14 or less, and containing no particles of 100 nm or more is prepared. [Selection diagram] None
Description
本発明はマイクロエマルション、及びマイクロエマルションの利用に関する。 The present invention relates to microemulsions and the use of microemulsions.
難水溶性物質の水溶化手法として乳剤（エマルション）化が知られている。例えば、生理活性を有する難水溶性薬剤は、乳剤化することにより、経口及び経皮吸収効率が向上することが知られている。また、乳剤化した粒子の粒子径が小さいほど、吸収効率が向上することも知られている。 Emulsion is known as a method for solubilizing poorly water-soluble substances. For example, it is known that oral and percutaneous absorption efficiency is improved by emulsifying a poorly water-soluble drug having a physiological activity. It is also known that the smaller the particle size of the emulsified particles, the higher the absorption efficiency.
例えば、特許文献１には、ココナツ油及びポリソルベート８０からなる系であって、ココナツ油とポリソルベート８０との重量比が１：４〜１：９である系に脂溶性機能成分を溶解した混合物を、水性媒体で希釈して得られるマイクロエマルションが開示されている。 For example, Patent Literature 1 discloses a system in which a fat-soluble functional component is dissolved in a system including coconut oil and polysorbate 80, in which the weight ratio of coconut oil to polysorbate 80 is 1: 4 to 1: 9. Microemulsions obtained by dilution with an aqueous medium are disclosed.
しかしながら、上述のような従来技術は、マイクロエマルションの乳剤化した粒子の粒径が依然として大きく、粒子径分布が広く、粒子径の均質性が不十分であるという問題がある。 However, the conventional techniques described above have the problem that the size of the emulsified particles of the microemulsion is still large, the particle size distribution is wide, and the uniformity of the particle size is insufficient.
本発明の一態様は、前記の問題点に鑑みてなされたものであり、乳剤化した粒子の粒子径が小さく、粒子径分布が狭く、且つ、粒子径の均質性が向上したマイクロエマルション、かかるマイクロエマルションを調製するための組成物、これらの製造方法、及びマイクロエマルションの利用物を提供することを目的とする。 One embodiment of the present invention has been made in view of the above problems, and a microemulsion in which the particle size of emulsified particles is small, the particle size distribution is narrow, and the uniformity of the particle size is improved. It is an object of the present invention to provide a composition for preparing a microemulsion, a production method thereof, and a use of the microemulsion.
本発明者らは、前記課題を解決するため鋭意検討した結果、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、オイルと、難水溶性機能性成分とを所定の割合で含む組成物を用いてマイクロエマルションを調製することにより、前記課題を解決することができることを独自に見出し、本発明を完成させるに至った。すなわち本発明の一実施形態は、以下の構成を含むものである。
〔１〕マイクロエマルションを調製するための組成物であって、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、オイルと、難水溶性機能性成分とを含み、前記オイルに対する前記界面活性剤成分の重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対する前記界面活性剤成分の重量比が、５．２０以上２００以下である、組成物。
〔２〕前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、前記難水溶性機能性成分に対する前記オイルの重量比が、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、前記難水溶性機能性成分に対する前記オイルの重量比が、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である、〔１〕に記載の組成物。
〔３〕〔１〕又は〔２〕に記載の組成物と、水性媒体とを含む、マイクロエマルション。
〔４〕〔３〕に記載のマイクロエマルションを含む、医薬品、機能性食品、又は化粧品。
〔５〕マイクロエマルションを調製するための組成物の製造方法であって、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、オイルと、難水溶性機能性成分とを混合する混合工程を含み、前記オイルに対する前記界面活性剤成分の重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対する前記界面活性剤成分の重量比が、５．２０以上２００以下である、製造方法。
〔６〕前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、前記難水溶性機能性成分に対する前記オイルの重量比が、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、前記難水溶性機能性成分に対する前記オイルの重量比が、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である、〔５〕に記載の製造方法。
〔７〕マイクロエマルションの製造方法であって、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、オイルと、難水溶性機能性成分とを混合する混合工程と、前記混合工程により得られた組成物と、水性媒体とを混合する工程とを含み、前記オイルに対する前記界面活性剤成分の重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対する前記界面活性剤成分の重量比が、５．２０以上２００以下である、マイクロエマルションの製造方法。
〔８〕前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、前記難水溶性機能性成分に対する前記オイルの重量比が、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、前記難水溶性機能性成分に対する前記オイルの重量比が、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である、〔７〕に記載のマイクロエマルションの製造方法。
〔９〕平均粒子径が１８ｎｍ以下であり、粒度分布指標が０．１４以下であり、且つ、１００ｎｍ以上の粒子を含まない単一分散の、マイクロエマルション。
The present inventors have conducted intensive studies to solve the above-described problems, and as a result, a surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil, an oil, and a poorly water-soluble functional component. The present inventors have uniquely found that the above problem can be solved by preparing a microemulsion using a composition containing at a predetermined ratio, and have completed the present invention. That is, one embodiment of the present invention includes the following configuration.
[1] A composition for preparing a microemulsion, comprising: a surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil; an oil; and a poorly water-soluble functional component. Wherein the weight ratio of the surfactant component to the oil is 9.20 to 240, and the weight ratio of the surfactant component to the total weight of the oil and the poorly water-soluble functional component is 5. A composition, which is 20 or more and 200 or less.
[2] When LogP of the poorly water-soluble functional component is 4.2 or more, the weight ratio of the oil to the poorly water-soluble functional component is [−0.38 × (of the poorly water-soluble functional component). (LogP) +5.169] or more and 2,000 or less, and when the LogP of the poorly water-soluble functional component is less than 4.2, the weight ratio of the oil to the poorly water-soluble functional component is [-4.955]. × (LogP of poorly water-soluble functional component) +23.56] or more and 2000 or less.
[3] A microemulsion comprising the composition according to [1] or [2], and an aqueous medium.
[4] A pharmaceutical, functional food, or cosmetic comprising the microemulsion according to [3].
[5] A method for producing a composition for preparing a microemulsion, comprising: a surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil; an oil; A mixing ratio of the surfactant component to the oil is from 9.20 to 240, and the surfactant is based on the total weight of the oil and the poorly water-soluble functional component. The production method, wherein the weight ratio of the components is from 5.20 to 200.
[6] When LogP of the poorly water-soluble functional component is 4.2 or more, the weight ratio of the oil to the poorly water-soluble functional component is [−0.38 × (of the poorly water-soluble functional component). (LogP) +5.169] or more and 2,000 or less, and when the LogP of the poorly water-soluble functional component is less than 4.2, the weight ratio of the oil to the poorly water-soluble functional component is [-4.955]. × (LogP of poorly water-soluble functional component) +23.56] or more and 2000 or less.
[7] A method for producing a microemulsion, which comprises mixing a surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil, an oil, and a poorly water-soluble functional component. And a step of mixing the composition obtained in the mixing step with an aqueous medium, wherein the weight ratio of the surfactant component to the oil is 9.20 or more and 240 or less. A method for producing a microemulsion, wherein the weight ratio of the surfactant component to the total weight of the water-soluble functional component is from 5.20 to 200.
[8] When LogP of the poorly water-soluble functional component is 4.2 or more, the weight ratio of the oil to the poorly water-soluble functional component is [−0.38 × (of the poorly water-soluble functional component). (LogP) +5.169] or more and 2,000 or less, and when the LogP of the poorly water-soluble functional component is less than 4.2, the weight ratio of the oil to the poorly water-soluble functional component is [-4.955]. × (LogP of poorly water-soluble functional component) +23.56] or more and 2000 or less, the method for producing a microemulsion according to [7].
[9] A monodisperse microemulsion having an average particle size of 18 nm or less, a particle size distribution index of 0.14 or less, and containing no particles of 100 nm or more.
本発明の一態様によれば、乳化粒子の粒子径が小さく、粒子径分布が狭く、且つ、粒子径の均質性が向上したマイクロエマルション、かかるマイクロエマルションを調製するための組成物、これらの製造方法、及びマイクロエマルションの利用物を提供することができる。 According to one embodiment of the present invention, a microemulsion having a small particle size of an emulsified particle, a narrow particle size distribution, and improved particle size homogeneity, a composition for preparing such a microemulsion, and production thereof Methods and microemulsion applications can be provided.
以下、本発明の実施の形態について、詳細に説明する。ただし、本発明はこれに限定されるものではなく、記述した範囲内で種々の変形を加えた態様で実施できるものである。また、本明細書中に記載された学術文献及び特許文献の全てが、本明細書中において参考として援用される。なお、本明細書において特記しない限り、数値範囲を表す「Ａ〜Ｂ」は、「Ａ以上、Ｂ以下」を意味する。 Hereinafter, embodiments of the present invention will be described in detail. However, the present invention is not limited to this, and can be implemented in variously modified forms within the described range. In addition, all of the academic documents and patent documents described in this specification are incorporated herein by reference. Unless otherwise specified in this specification, “A to B” representing a numerical range means “A or more and B or less”.
〔１．マイクロエマルションを調製するための組成物〕
本発明の一実施形態はマイクロエマルションを調製するための組成物に係る。ここで、本明細書において、「マイクロエマルション」とは、水、オイル、及び界面活性剤で作られる、粒径が数ｎｍ〜数十ｎｍ程度の光学的に透明な又は半透明の微小液滴分散系をいう。前記微小液滴は後述するミセルに該当し、マイクロエマルションの乳化粒子（乳剤化した粒子）である。本発明の一実施形態に係る、マイクロエマルションを調製するための組成物に、水性媒体を添加することにより、マイクロエマルションが形成される。
[1. Composition for preparing microemulsion)
One embodiment of the present invention is directed to a composition for preparing a microemulsion. Here, in the present specification, a “microemulsion” is an optically transparent or translucent microdroplet made of water, oil, and a surfactant and having a particle size of about several nm to several tens nm. Refers to a dispersion system. The microdroplets correspond to micelles described below, and are emulsified particles (emulsified particles) of a microemulsion. A microemulsion is formed by adding an aqueous medium to a composition for preparing a microemulsion according to one embodiment of the present invention.
本発明の一実施形態に係るマイクロエマルションを調製するための組成物（以下、本明細書において、「マイクロエマルション調製用組成物」と称することがある。）は、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、オイルと、難水溶性機能性成分とを含み、前記オイルに対する前記界面活性剤成分の重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対する前記界面活性剤成分の重量比が、５．２０以上２００以下である。 A composition for preparing a microemulsion according to one embodiment of the present invention (hereinafter, may be referred to as a “composition for preparing a microemulsion” in the present specification) is composed of polysorbate 80 and polyoxyethylene castor oil. A surfactant component containing at least one selected from the group consisting of an oil and a poorly water-soluble functional component, wherein the weight ratio of the surfactant component to the oil is from 9.20 to 240, The weight ratio of the surfactant component to the total weight of the oil and the poorly water-soluble functional component is from 5.20 to 200.
本発明のより好ましい一実施形態に係るマイクロエマルションを調製するための組成物は、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、オイルと、難水溶性機能性成分とを含み、前記オイルに対する前記界面活性剤成分の重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対する前記界面活性剤成分の重量比が、５．２０以上２００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、前記難水溶性機能性成分に対する前記オイルの重量比が、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、前記難水溶性機能性成分に対する前記オイルの重量比が、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である。 A composition for preparing a microemulsion according to a more preferred embodiment of the present invention includes a surfactant component containing at least any one selected from polysorbate 80 and polyoxyethylene castor oil, an oil, and a poorly water-soluble component. A weight ratio of the surfactant component to the oil is 9.20 or more and 240 or less, and a weight of the surfactant component with respect to a total weight of the oil and the poorly water-soluble functional component. When the ratio is 5.20 or more and 200 or less and LogP of the poorly water-soluble functional component is 4.2 or more, the weight ratio of the oil to the poorly water-soluble functional component is [−0.38 × (LogP of poorly water-soluble functional component) +5.169] or more and 2,000 or less, and when LogP of the poorly water-soluble functional component is less than 4.2, The weight ratio of the oil relative to soluble functional ingredient, [- 4.955 × (poorly water-soluble functional ingredient LogP) +23.56] or more and 2000 or less.
（界面活性剤成分）
本発明の一実施形態に係るマイクロエマルション調製用組成物は、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分を含む。
(Surfactant component)
The composition for preparing a microemulsion according to one embodiment of the present invention includes a surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil.
より好ましくは、前記マイクロエマルション調製用組成物は、当該組成物に含まれる界面活性剤成分の主成分としてポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む。ここで、「主成分として」とは、前記マイクロエマルション調製用組成物に含まれる界面活性剤成分の全重量に対して、好ましくは８０重量％以上であり、より好ましくは８５重量％以上であり、さらに好ましくは９０重量％以上であり、特に好ましくは９５重量％以上であり、最も好ましくは１００重量％である。 More preferably, the composition for preparing a microemulsion contains at least one selected from polysorbate 80 and polyoxyethylene castor oil as a main component of a surfactant component contained in the composition. Here, “as a main component” is preferably at least 80% by weight, more preferably at least 85% by weight, based on the total weight of the surfactant component contained in the composition for preparing a microemulsion. The content is more preferably 90% by weight or more, particularly preferably 95% by weight or more, and most preferably 100% by weight.
本発明の一実施形態において、ポリオキシエチレンヒマシ油は、ヒマシ油に酸化エチレンが付加重合した化合物である。酸化エチレンの平均付加モル数は特に限定されるものではないが、好ましくは２〜１００であり、より好ましくは１０〜５０である。前記ポリオキシエチレンヒマシ油としては、例えば、ＮＩＫＫＯＬ ＣＯ−３、ＮＩＫＫＯＬ ＣＯ−１０（日光ケミカルズ）；ＥＭＡＬＥＸ Ｃ−２０、ＥＭＡＬＥＸ Ｃ−３０、ＥＭＡＬＥＸ Ｃ−４０、ＥＭＡＬＥＸ Ｃ−５０（日本エマルジョン）；及びＫｏｌｌｉｐｈｏｒ ＥＬ（ＢＡＳＦ）を挙げることができる。これらは、１種類を単独で用いてもよいし、２種類以上を組み合わせて用いてもよい。前記ポリオキシエチレンヒマシ油はより好ましくは、Ｋｏｌｌｉｐｈｏｒ ＥＬである。 In one embodiment of the present invention, polyoxyethylene castor oil is a compound obtained by addition polymerization of castor oil with ethylene oxide. The average number of moles of ethylene oxide added is not particularly limited, but is preferably 2 to 100, and more preferably 10 to 50. Examples of the polyoxyethylene castor oil include NIKKOL CO-3, NIKKOL CO-10 (Nikko Chemicals); EMALEX C-20, EMALEX C-30, EMALEX C-40, and EMALEX C-50 (Nippon Emulsion); Kolliphor EL (BASF) can be mentioned. One of these may be used alone, or two or more may be used in combination. The polyoxyethylene castor oil is more preferably Kolliphor EL.
本発明の一実施形態において、前記界面活性剤成分は、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含んでいればよい。前記界面活性剤成分が、ポリソルベート８０及びポリオキシエチレンヒマシ油を両方含む場合には、ポリソルベート８０とポリオキシエチレンヒマシ油との使用割合は特に限定されるものではなく、重量基準で、ポリソルベート８０：ポリオキシエチレンヒマシ油が、１：９９〜９９：１である。 In one embodiment of the present invention, the surfactant component may include at least one selected from polysorbate 80 and polyoxyethylene castor oil. When the surfactant component contains both polysorbate 80 and polyoxyethylene castor oil, the usage ratio of polysorbate 80 and polyoxyethylene castor oil is not particularly limited, and the weight of polysorbate 80: Polyoxyethylene castor oil is 1: 99-99: 1.
ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分を上記範囲で含むことにより、当該マイクロエマルション調製用組成物から、乳化粒子径が小さく、粒子径分布が狭く、且つ、粒子径の均質性が向上したマイクロエマルションを調製することができる。 By containing a surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil in the above range, from the microemulsion preparation composition, the emulsified particle size is small, the particle size distribution is narrow, In addition, a microemulsion having improved particle size homogeneity can be prepared.
（オイル）
本発明の一実施形態に係るマイクロエマルション調製用組成物は、オイルを含む。前記オイルは、通常、食用、医薬用、化粧品用に使用されうるオイルであれば特に限定されるものではなく、例えば、アボカド油、オリーブ油、ゴマ油、アーモンド油、ベルガモット油、ツバキ油、月見草油、マカデミアンナッツ油、トウモロコシ油、ナタネ油、パーシック油、小麦胚芽油、サザンカ油、ヒマシ油、アマニ油、サフラワー油、綿実油、エノ油、大豆油、落花生油、茶実油、カヤ油、コメヌカ油、キリ油、キャノーラ油、紅花油、ククイナッツ油、グレープシード油、ヘーゼルナッツ油、ヒマワリ油、ローズヒップ油、ピスタチオナッツ油、ヤシ油（ココナッツ油）、及び植物性スクワラン等の天然由来油；中鎖脂肪酸トリグリセリド、ミリスチン酸イソプロピル、ミリスチン酸オクチルドデシル、及び流動パラフィン等の合成油を挙げることができる。中でも、前記天然由来油は植物油であることがより好ましい。また、生体への吸収性及び薬物等の機能性成分の溶解性の観点から、前記オイルは、より好ましくは、大豆油、中鎖脂肪酸トリグリセリド、ヤシ油（ココナッツ油）、ベルガモット油、ローズヒップ油、及びアーモンド油であり、さらに好ましくは、大豆油及び中鎖脂肪酸トリグリセリドである。前記オイルは一種のみを用いてもよく、二種以上を併用してもよい。なお、前記オイルは、凝固点が２５℃以下のオイルであることがより好ましい。室温（２５℃）で固化することもあるパーム油やホホバ油等のワックス成分を多く含む植物油や牛脂、豚脂等は、エマルションの安定性を損なう場合があるため好ましくない。
(oil)
The composition for preparing a microemulsion according to one embodiment of the present invention contains an oil. The oil is usually not particularly limited as long as it is an oil that can be used for food, medicine, and cosmetics.For example, avocado oil, olive oil, sesame oil, almond oil, bergamot oil, camellia oil, evening primrose oil, Macadamian nut oil, corn oil, rapeseed oil, persic oil, wheat germ oil, sasanqua oil, castor oil, linseed oil, safflower oil, cottonseed oil, eno oil, soybean oil, peanut oil, teaseed oil, kaya oil, rice bran Oils, naturally occurring oils such as oil, drill oil, canola oil, safflower oil, kuku nut oil, grape seed oil, hazelnut oil, sunflower oil, rosehip oil, pistachio nut oil, coconut oil (coconut oil), and vegetable squalane; Of fatty acid triglyceride, isopropyl myristate, octyldodecyl myristate, liquid paraffin, etc. Oil can be mentioned. Among them, the natural oil is more preferably a vegetable oil. In addition, from the viewpoints of absorbability in a living body and solubility of a functional component such as a drug, the oil is more preferably soybean oil, medium-chain fatty acid triglyceride, coconut oil (coconut oil), bergamot oil, or rosehip oil. And almond oil, more preferably soybean oil and medium chain fatty acid triglycerides. The oil may be used alone or in combination of two or more. The oil is more preferably an oil having a freezing point of 25 ° C. or lower. Vegetable oils, beef tallow, lard, etc. containing a large amount of wax components such as palm oil and jojoba oil which may be solidified at room temperature (25 ° C.) are not preferred because they may impair the stability of the emulsion.
前記オイルを用いることにより、乳化粒子の粒子径が小さく安定なマイクロエマルション得ることができるため、好ましい。 The use of the oil is preferable because a stable microemulsion having a small particle size of emulsified particles can be obtained.
（難水溶性機能性成分）
本発明の一実施形態に係るマイクロエマルション調製用組成物は、難水溶性機能性成分を含む。
(Poorly water-soluble functional ingredient)
The composition for preparing a microemulsion according to one embodiment of the present invention contains a poorly water-soluble functional component.
本明細書において、「難水溶性」とは、日本薬局方に規定される「溶けにくい」「極めて溶けにくい」及び「ほとんど溶けない」を意味し、２０℃の水に対する溶解度が１０ｍｇ/ｍｌ以下であることをいう。より好ましくは、「難水溶性」とは、日本薬局方に規定される「極めて溶けにくい」及び「ほとんど溶けない」を意味し、２０℃の水に対する溶解度が１ｍｇ/ｍｌ以下であることをいう。前記難水溶性機能性成分は、水に対する溶解度が低いため、前記オイルに溶解して、マイクロエマルションとすることにより、水性媒体中に分散させることができる。前記難水溶性機能性成分は、難水溶性であって、脂溶性であることが好ましい。 In the present specification, the term "poorly water-soluble" means "poorly soluble", "extremely insoluble" and "almost insoluble" defined in the Japanese Pharmacopoeia, and the solubility in water at 20 ° C is 10 mg / ml or less. It means that. More preferably, "poorly water-soluble" means "extremely insoluble" and "almost insoluble" defined in the Japanese Pharmacopoeia, and means that the solubility in water at 20 ° C is 1 mg / ml or less. . Since the poorly water-soluble functional component has low solubility in water, it can be dispersed in an aqueous medium by dissolving in the oil to form a microemulsion. It is preferable that the poorly water-soluble functional component is poorly water-soluble and fat-soluble.
また、本明細書において「機能性成分」とは、何らかの機能を有する成分であれば特に限定されるものではないが、例えば、生体内に吸収されて種々の機能的効果を生じさせる成分、及びコーティング剤に含まれて種々の機能的効果を生じさせる成分等を挙げることができる。 Further, in the present specification, the "functional component" is not particularly limited as long as it has a certain function, for example, a component that is absorbed into a living body to produce various functional effects, and Components that cause various functional effects contained in the coating agent can be exemplified.
前述の、生体内に吸収されて種々の機能的効果を生じさせる成分には、疾病又は病態の、抑制、診断、緩和、治療、治癒又は予防に使用される薬理活性を有する成分、生体に対して所定の栄養的又は健康上の利益を提供する成分等が含まれる。特にそのままでは生体吸収性に劣る難水溶性機能性成分においては、本発明の組成物とする効果が顕著である。 The above-mentioned components that are absorbed into a living body and produce various functional effects include components having pharmacological activity used for suppressing, diagnosing, alleviating, treating, curing or preventing diseases or conditions, Ingredients that provide certain nutritional or health benefits. Particularly, in the case of a poorly water-soluble functional component which is inferior in bioabsorbability as it is, the effect of the composition of the present invention is remarkable.
前記薬理活性を有する機能性成分は医薬品等に用いられる成分である。薬理活性を有する難水溶性機能性成分としては、特に限定されるものではないが、例えば、パクリタキセル、シクロスポリン、インドメタシン、テルフェナジン、フロセミド、アセタゾールアミド、コリスチン、メベンダゾール、アルベンダゾール、ニロチニブ、ロルメタゼパム、及び、ブロマゼパム等を挙げることができる。 The functional component having the pharmacological activity is a component used in pharmaceuticals and the like. Examples of the poorly water-soluble functional ingredient having pharmacological activity include, but are not particularly limited to, paclitaxel, cyclosporine, indomethacin, terfenadine, furosemide, acetazolamide, colistin, mebendazole, albendazole, nilotinib, lormetazepam, And bromazepam.
前記栄養的又は健康上の利益を提供する成分としては、例えば、特別用途食品、保健機能食品（特定保健用食品、栄養機能食品）、機能性食品、栄養補助食品、健康補助食品、栄養強化食品、栄養調整食品、サプリメント等に用いられる成分を挙げることができる。かかる難水溶性機能性成分としては、例えば、コエンザイムＱ１０（以下、本明細書において、ＣｏＱ１０と称することがある。）、クルクミン、トコトリエノール、テストステロン、メントール、カロテノイド（α−カロテン、β−カロテン、ルテイン、リコペン、アスタキサンチン、ゼアキサンチン、クリプトキサンチン、フコキサンチン、及びキサントフィル等）、レスベラトロル、ドコサヘキサエン酸（ＤＨＡ）、エイコサペンタエン酸（ＥＰＡ）、脂溶性ビタミン（ビタミンＡ、ビタミンＤ、ビタミンＥ（トコフェロール）、ビタミンＫ）、セサミン、α−リポ酸、ノコギリヤシエキス（オレイン酸、ラウリン酸、ミリスチン酸、リノール酸、パルミチン酸）、セントジョーンズワート（ヒペリシン）、ロイヤルゼリー（デセン酸）、ヘスペリジン、ノビレチン、ケルセチン、ケンフェロール、ミリシトリン、カテキン、ダイゼイン、グリシテイン、ゲニステイン、ミリセチン、及びスチルベン等、並びにこれらの２種以上の組合せを挙げることができる。 Examples of the ingredients that provide nutritional or health benefits include special use foods, health functional foods (specified health foods, nutritional functional foods), functional foods, dietary supplements, health supplements, and enriched foods. And ingredients used in nutritionally adjusted foods, supplements and the like. Examples of such poorly water-soluble functional components include coenzyme Q10 (hereinafter sometimes referred to as CoQ10 in the present specification), curcumin, tocotrienol, testosterone, menthol, carotenoids (α-carotene, β-carotene, lutein). , Lycopene, astaxanthin, zeaxanthin, cryptoxanthin, fucoxanthin, xanthophyll, etc.), resveratrol, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), fat-soluble vitamins (vitamin A, vitamin D, vitamin E (tocopherol), vitamins) K), sesamin, α-lipoic acid, saw palmetto extract (oleic acid, lauric acid, myristic acid, linoleic acid, palmitic acid), St. John's wort (hypericin), royal jelly (decenoic acid) Hesperidin, nobiletin may quercetin, kaempferol, myricitrin, catechin, daidzein, glycitein, genistein, be mentioned myricetin, and stilbenes, and the like, as well as combinations of two or more thereof.
或いは、前記栄養的又は健康上の利益を提供する成分としては、肌改善成分、保湿成分、抗老化成分、育毛成分、及び発毛成分等の化粧品等に用いられる成分を挙げることができる。難水溶性のかかる機能性成分としては、例えば、コエンザイムＱ１０、クルクミン、トコトリエノール、カロテノイド（α−カロテン、β−カロテン、ルテイン、リコペン、アスタキサンチン、ゼアキサンチン、クリプトキサンチン、フコキサンチン、及びキサントフィル等）、レスベラトロル、ドコサヘキサエン酸（ＤＨＡ）、エイコサペンタエン酸（ＥＰＡ）、脂溶性ビタミン（ビタミンＡ、ビタミンＤ、ビタミンＥ（トコフェロール）、ビタミンＫ）、セサミン、及びα−リポ酸、並びにこれらの２種以上の組合せを挙げることができる。 Alternatively, examples of the component providing nutritional or health benefits include components used in cosmetics such as a skin improving component, a moisturizing component, an anti-aging component, a hair growth component, and a hair growth component. Examples of such poorly water-soluble functional components include coenzyme Q10, curcumin, tocotrienol, carotenoids (α-carotene, β-carotene, lutein, lycopene, astaxanthin, zeaxanthin, cryptoxanthin, fucoxanthin, xanthophyll, etc.), resveratrol , Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), fat-soluble vitamins (vitamin A, vitamin D, vitamin E (tocopherol), vitamin K), sesamin, and α-lipoic acid, and combinations of two or more thereof Can be mentioned.
また、前記機能性成分には、発色成分等の、印刷等の工業分野でコーティング剤として用いられる成分も含まれる。難水溶性のかかる機能性成分としては、例えば、コエンザイムＱ１０、クルクミン、及びカロテノイド（α−カロテン、β−カロテン、ルテイン、リコペン、アスタキサンチン、ゼアキサンチン、クリプトキサンチン、フコキサンチン、及びキサントフィル等）等並びにこれらの２種以上の組合せを挙げることができる。 The functional components also include components used as coating agents in industrial fields such as printing, such as coloring components. Examples of such poorly water-soluble functional components include coenzyme Q10, curcumin, and carotenoids (such as α-carotene, β-carotene, lutein, lycopene, astaxanthin, zeaxanthin, cryptoxanthin, fucoxanthin, and xanthophyll) and the like. And two or more combinations of the above.
また、前記機能性成分には、ＤＤＴ（ジクロロジフェニルトリクロロエタン）、テブフェンピラド、及びフェノキシカルブ等の殺虫剤として用いられる成分も含まれる。 The functional components also include components used as insecticides such as DDT (dichlorodiphenyltrichloroethane), tebufenpyrad, and phenoxycarb.
（各成分の重量比）
本発明の一実施形態にかかるマイクロエマルション調製用組成物は、下記（i）及び（ii）を満たすことにより、水性媒体を混合したときに、乳化粒子の粒子径が小さく、粒子径分布が狭く、且つ、乳化粒子の粒子径の均質性が向上したマイクロエマルションを実現することができるという効果を得ることができる。
（i）前記オイルに対する前記ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分の重量比（ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分／オイル）は、９．２０以上２４０以下である。
（ii）前記オイルと前記難水溶性機能性成分との合計重量に対するポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分の重量比（ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分／（オイル＋難水溶性機能性成分））は、５．２０以上２００以下である。
(Weight ratio of each component)
The composition for preparing a microemulsion according to one embodiment of the present invention satisfies the following (i) and (ii), whereby, when an aqueous medium is mixed, the particle size of emulsified particles is small and the particle size distribution is narrow. In addition, it is possible to obtain an effect that a microemulsion in which the homogeneity of the particle diameter of emulsified particles is improved can be realized.
(I) a weight ratio of a surfactant component containing at least one selected from the polysorbate 80 and polyoxyethylene castor oil to the oil (an interface containing at least one selected from polysorbate 80 and polyoxyethylene castor oil); (Activator component / oil) is from 9.20 to 240.
(Ii) the weight ratio of the surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil to the total weight of the oil and the poorly water-soluble functional component (polysorbate 80 and polyoxyethylene castor) The surfactant component containing at least any one selected from oils / (oil + poorly water-soluble functional component)) is 5.20 or more and 200 or less.
また、本発明の一実施形態にかかるマイクロエマルション調製用組成物は、上記（i）及び（ii）に加えて、下記（iii）を満たすことにより、水性媒体を混合したときに、乳化粒子の粒子径が小さく、粒子径分布が狭く、且つ、乳化粒子の粒子径の均質性が向上するとともに、安定性に優れたマイクロエマルションを実現することができるという効果を得ることができる。
（iii）前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、前記難水溶性機能性成分に対する前記オイルの重量比（オイル／難水溶性機能性成分）が、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、前記難水溶性機能性成分に対する前記オイルの重量比（オイル／難水溶性機能性成分）が、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である。
Further, the composition for preparing a microemulsion according to one embodiment of the present invention satisfies the following (iii) in addition to the above (i) and (ii), so that when mixed with an aqueous medium, The effect that the particle diameter is small, the particle diameter distribution is narrow, the homogeneity of the particle diameter of the emulsified particles is improved, and a microemulsion having excellent stability can be obtained.
(Iii) When LogP of the poorly water-soluble functional component is 4.2 or more, the weight ratio of the oil to the poorly water-soluble functional component (oil / poorly water-soluble functional component) is [-0. 38 × (LogP of poorly water-soluble functional component) +5.169] or more and 2,000 or less, and when LogP of the poorly water-soluble functional component is less than 4.2, the oil for the poorly water-soluble functional component Is not less than [−4.955 × (Log P of poorly water-soluble functional component) +23.56] or more and not more than 2000.
前記オイルに対する前記界面活性剤成分の重量比は、９．２０以上２４０以下であればよいが、その下限は、より好ましくは９．４０であり、さらに好ましくは９．６０であり、さらにより好ましくは１０であり、特に好ましくは２０である。 The weight ratio of the surfactant component to the oil may be 9.20 or more and 240 or less, and the lower limit is more preferably 9.40, still more preferably 9.60, and still more preferably. Is 10, particularly preferably 20.
また、前記オイルと前記難水溶性機能性成分との合計重量に対する前記界面活性剤成分の重量比は、５．２０以上２００以下であればよいが、その下限は、より好ましくは５．８であり、さらに好ましくは６．０であり、さらにより好ましくは８．０である。 Further, the weight ratio of the surfactant component to the total weight of the oil and the poorly water-soluble functional component may be from 5.20 to 200, and the lower limit is more preferably 5.8. Yes, more preferably 6.0, and even more preferably 8.0.
（ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分／オイル）を９．２０以上、かつ、（ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分／（オイル＋難水溶性機能性成分））を５．２０以上とすることにより、乳化粒子の粒子径が小さく、粒子径分布が狭く、且つ、乳化粒子の粒子径の均質性が向上したマイクロエマルションを得ることができる。また、（ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分／オイル）を９．６０以上、かつ、〔ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分／（オイル＋難水溶性機能性成分）〕を５．２０以上とすることにより、前記効果に加えて、さらに乳化粒子の粒子径をより小さくすることができるため好ましい。 9.20 or more (a surfactant component / oil containing at least one selected from polysorbate 80 and polyoxyethylene castor oil) and (at least one selected from polysorbate 80 and polyoxyethylene castor oil) By setting the content of the surfactant component / (oil + poorly water-soluble functional component) to 5.20 or more, the particle size of the emulsified particles is small, the particle size distribution is narrow, and the particle size of the emulsified particles is uniform. A microemulsion having improved properties can be obtained. Further, 9.60 or more (a surfactant component / oil containing at least one selected from polysorbate 80 and polyoxyethylene castor oil) and [at least any one selected from polysorbate 80 and polyoxyethylene castor oil. Surfactant component / (oil + poorly water-soluble functional component)] of 5.20 or more is preferable because, in addition to the above effects, the particle size of emulsified particles can be further reduced. .
前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、前記難水溶性機能性成分に対する前記オイルの重量比（オイル／難水溶性機能性成分）は、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であればよいが、その下限は、より好ましくは［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．９］以上であり、さらに好ましくは［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋６．７］以上である。前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、（オイル／難水溶性機能性成分）が［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上であれば、前記難水溶性機能性成分を安定的に溶解するためのオイルの量が充分となり、安定性に優れたマイクロエマルションを実現することができるため好ましい。 When LogP of the poorly water-soluble functional component is 4.2 or more, the weight ratio of the oil to the poorly water-soluble functional component (oil / poorly water-soluble functional component) is [−0.38 × ( The water-soluble functional component (LogP) +5.169] or more and 2000 or less may be used, and the lower limit is more preferably [-0.38 × (LogP of the poorly water-soluble functional component) +5.9] or more. And more preferably [−0.38 × (LogP of poorly water-soluble functional component) +6.7] or more. When LogP of the poorly water-soluble functional component is 4.2 or more, (oil / poorly water-soluble functional component) is [−0.38 × (LogP of the poorly water-soluble functional component) +5.169] or more. This is preferable because the amount of oil for stably dissolving the poorly water-soluble functional component becomes sufficient and a microemulsion having excellent stability can be realized.
また、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、前記難水溶性機能性成分に対する前記オイルの重量比（オイル／難水溶性機能性成分）は、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下であればよいが、その下限は、より好ましくは［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２６］以上であり、さらに好ましくは［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２９］以上である。前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、（オイル／難水溶性機能性成分）が［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上であれば、前記難水溶性機能性成分を安定的に溶解するためのオイルの量が充分となり、安定性に優れたマイクロエマルションを実現することができるため好ましい。 When LogP of the poorly water-soluble functional component is less than 4.2, the weight ratio of the oil to the poorly water-soluble functional component (oil / poorly water-soluble functional component) is [−4.955]. X (LogP of poorly water-soluble functional component) +23.56] or more and 2000 or less, but the lower limit is more preferably [−4.955 × (LogP of poorly water-soluble functional component) +26] or more. And more preferably [−4.955 × (LogP of poorly water-soluble functional component) +29] or more. When LogP of the poorly water-soluble functional component is 4.2 or more, (oil / poorly water-soluble functional component) is [−4.955 × (LogP of the poorly water-soluble functional component) +23.56] or more. This is preferable because the amount of oil for stably dissolving the poorly water-soluble functional component is sufficient, and a microemulsion having excellent stability can be realized.
ここで、ＬｏｇＰとは、化学物質の１−オクタノール／水又は緩衝液分配係数の常用対数値であり、本明細書において、ＬｏｇＰとは、ＯＥＣＤ ＧＵＩＤＥＬＩＮＥ ＦＯＲ ＴＨＥ ＴＥＳＴＩＮＧ ＯＦ ＣＨＥＭＩＣＡＬＳ, “Ｐａｒｔｉｔｉｏｎ Ｃｏｅｆｆｉｃｉｅｎｔ (ｎ−ｏｃｔａｎｏｌ/ｗａｔｅｒ): Ｓｈａｋｅ Ｆｌａｓｋ Ｍｅｔｈｏｄ”によるフラスコ振盪法によって測定された値をいう。ＬｏｇＰの値が大きいほどその化学物質の親油性が高い。言い換えれば、ＬｏｇＰの値が大きいほどその化学物質の脂溶性が高くなる。 Here, LogP is a common logarithm value of 1-octanol / water or buffer partition coefficient of a chemical substance, and in this specification, LogP is OECD GUIDELINE FOR THE TESTING OF CHEMICALS, "Partition Coefficient (n- octanol / water): refers to the value measured by the flask shaking method according to the Shake Flash Method. The higher the value of LogP, the higher the lipophilicity of the chemical. In other words, the larger the value of LogP, the higher the fat solubility of the chemical substance.
本発明の一実施形態に係るマイクロエマルション中にて、前記オイルは、前記難水溶性機能性成分の溶媒として働く。本発明者らは、前記難水溶性機能性成分の親油性に着目した。すなわち、本発明者らは、前記難水溶性機能性成分の種類が異なれば、その極性も変わるので、前記難水溶性機能性成分を安定的に溶解するために必要なオイルの量も変わるのではないかと考えた。そして、種々の検討結果から、前記難水溶性機能性成分に対する前記オイルの重量比（オイル／難水溶性機能性成分）を上記（iii）を満たす範囲としたときに、安定なエマルションが得られることを見出した。 In the microemulsion according to one embodiment of the present invention, the oil functions as a solvent for the poorly water-soluble functional component. The present inventors have focused on the lipophilicity of the poorly water-soluble functional component. That is, the present inventors have found that, if the type of the poorly water-soluble functional component is different, the polarity also changes, so that the amount of oil required to stably dissolve the poorly water-soluble functional component also changes. I thought it might be. From various examination results, a stable emulsion can be obtained when the weight ratio of the oil to the poorly water-soluble functional component (oil / poorly water-soluble functional component) is in the range satisfying the above (iii). I found that.
〔２．マイクロエマルション〕
本発明の一実施形態に係るマイクロエマルションは、前記マイクロエマルション調製用組成物と水性媒体とを含む。
[2. Microemulsion)
A microemulsion according to one embodiment of the present invention includes the composition for preparing a microemulsion and an aqueous medium.
本明細書において、「水性媒体」とは、水を含んでいる媒体であれば特に限定されるものではない。前記水性媒体としては、例えば、水、気泡水、果汁、野菜ジュース、ソフトドリンク、牛乳、ヨーグルト飲料、豆乳、茶飲料、スポーツ飲料、及び栄養ドリンク等を挙げることができる。前記「水」とは、例えば、超純水（ＭｉｌｌｉＱ（登録商標）水）、蒸留水、イオン交換水等のいわゆる水であってもよいし、リン酸緩衝溶液等の各種緩衝液、生理食塩水をも含む趣旨である。前記水性媒体は一種のみを用いてもよく、二種以上を併用してもよい。 In the present specification, the “aqueous medium” is not particularly limited as long as it is a medium containing water. Examples of the aqueous medium include water, bubbled water, fruit juice, vegetable juice, soft drink, milk, yogurt drink, soy milk, tea drink, sports drink, and energy drink. The “water” may be, for example, so-called water such as ultrapure water (MilliQ (registered trademark) water), distilled water, ion-exchanged water, various buffers such as a phosphate buffer solution, and physiological saline. The purpose is to include water. The aqueous medium may be used alone or in combination of two or more.
本発明の一実施形態に係るマイクロエマルションに含まれる前記水性媒体の含有量は、マイクロエマルションを形成できる量であれば特に限定されないが、マイクロエマルションの総重量に対して、好ましくは５０〜９９．９重量％であり、より好ましくは６０〜９５重量％であり、さらに好ましくは７０〜９０重量％である。 The content of the aqueous medium contained in the microemulsion according to one embodiment of the present invention is not particularly limited as long as the microemulsion can be formed, but is preferably from 50 to 99.% based on the total weight of the microemulsion. It is 9% by weight, more preferably 60-95% by weight, even more preferably 70-90% by weight.
マイクロエマルションに含まれる前記水性媒体の含有量が５０重量％以上であれば、マイクロエマルションを好適に形成できるため好ましい。また、マイクロエマルションに含まれる前記水性媒体の含有量が９９．９重量％以下であれば、難水溶性機能性成分の濃度が低くなりすぎないため好ましい。 It is preferable that the content of the aqueous medium contained in the microemulsion is 50% by weight or more, since the microemulsion can be suitably formed. Further, when the content of the aqueous medium contained in the microemulsion is 99.9% by weight or less, the concentration of the poorly water-soluble functional component is preferably not too low.
本発明の一実施形態に係るマイクロエマルションにおいて、前記ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、前記オイルとは、ミセルを形成する。すなわち、前記オイルに溶解した前記難水溶性機能性成分の周囲を、前記界面活性剤成分が疎水基を内側にして囲み、ミセルが形成される。このミセルがマイクロエマルションの乳化粒子である。 In the microemulsion according to one embodiment of the present invention, a surfactant component containing at least one selected from the group consisting of polysorbate 80 and polyoxyethylene castor oil, and the oil form micelles. That is, the surfactant component surrounds the periphery of the poorly water-soluble functional component dissolved in the oil with the hydrophobic group inside, thereby forming micelles. These micelles are emulsified particles of the microemulsion.
前記乳化粒子の平均粒子径は、好ましくは１８ｎｍ以下である。前記乳化粒子の平均粒子径が１８ｎｍ以下であれば、前記難水溶性機能性成分の生体への吸収効率を改善できるため好ましい。また、前記乳化粒子の平均粒子径が小さいことにより、透明なマイクロエマルションを得ることができる。なお、ここで、乳化粒子の平均粒子径とは、Zetasizer Nano ZS(Malvern Institutes社製)を用いて、測定モード“size-small-vol-cell×1.SOP”によって測定した値をいう。 The average particle size of the emulsified particles is preferably 18 nm or less. When the average particle diameter of the emulsified particles is 18 nm or less, the absorption efficiency of the poorly water-soluble functional component into a living body can be improved, which is preferable. In addition, a transparent microemulsion can be obtained because the average particle size of the emulsified particles is small. Here, the average particle size of the emulsified particles refers to a value measured in a measurement mode “size-small-vol-cell × 1.SOP” using Zetasizer Nano ZS (manufactured by Malvern Institutes).
また、前記乳化粒子のＰＤＩ（粒度分布指標）は、好ましくは０．１４以下である。前記乳化粒子のＰＤＩ（粒度分布指標）が、０．１４以下であれば、生体への吸収性に優れた前記乳化粒子の平均粒子径が１８ｎｍ以下の乳化粒子を多く含み、安定性に優れたマイクロエマルションを実現することができるため好ましい。ここで、前記乳化粒子のＰＤＩ（粒度分布指標）は、Zetasizer Nano ZS(Malvern Institutes社製)を用いて、“size-small-vol-cell×1.SOP”によって測定した値をいう。 The PDI (particle size distribution index) of the emulsified particles is preferably 0.14 or less. When the PDI (particle size distribution index) of the emulsified particles is 0.14 or less, the emulsified particles having excellent absorbability to a living body contain many emulsified particles having an average particle diameter of 18 nm or less, and have excellent stability. This is preferable because a microemulsion can be realized. Here, the PDI (particle size distribution index) of the emulsified particles refers to a value measured by “size-small-vol-cell × 1.SOP” using Zetasizer Nano ZS (manufactured by Malvern Institutes).
また、前記マイクロエマルションは、１００ｎｍ以上の粒子（サブピーク）を含まない単一分散の分散体であることが好ましい。前記マイクロエマルションが１００ｎｍ以上の粒子（サブピーク）を含まない、乳化粒子の粒子径の均質性が向上した単一分散の分散体であれば、透明で、生体への吸収性に優れ、なおかつ安定性に優れたマイクロエマルションを実現することができるため好ましい。 Further, the microemulsion is preferably a monodispersed dispersion containing no particles (subpeaks) of 100 nm or more. If the microemulsion is a monodispersed dispersion containing no particles (sub-peak) of 100 nm or more and having improved particle size homogeneity of the emulsified particles, it is transparent, has excellent absorbability to a living body, and is stable. This is preferable since a microemulsion excellent in the above can be realized.
また、前記マイクロエマルションは、安定性に優れた水中油型マイクロエマルションであり、２５℃において、少なくとも１４日間は安定な状態で存在する。 The microemulsion is an oil-in-water microemulsion having excellent stability, and is present in a stable state at 25 ° C. for at least 14 days.
〔３．マイクロエマルション調製用組成物の製造方法〕
本発明の一実施形態に係るマイクロエマルション調製用組成物の製造方法は、前記ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、前記オイルと、前記難水溶性機能性成分とを混合する混合工程を含んでいればよい。ここで、前記界面活性剤成分と、前記オイルと、前記難水溶性機能性成分との混合は、前記オイルに対する前記界面活性剤成分の重量比が９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対する前記界面活性剤成分の重量比が５．２０以上２００以下であるように行う。
[3. Production method of microemulsion preparation composition)
The method for producing a composition for preparing a microemulsion according to one embodiment of the present invention includes a surfactant component containing at least one selected from the polysorbate 80 and polyoxyethylene castor oil, the oil, and the poorly water-soluble component. What is necessary is just to include the mixing process of mixing with a sexually-functional component. Here, the mixture of the surfactant component, the oil, and the poorly water-soluble functional component has a weight ratio of the surfactant component to the oil of 9.20 or more and 240 or less. The operation is performed so that the weight ratio of the surfactant component to the total weight of the poorly water-soluble functional component is 5.20 or more and 200 or less.
本発明の一実施形態に係るマイクロエマルション調製用組成物の製造方法は、前記界面活性剤成分と、前記オイルと、前記難水溶性機能性成分とを混合する混合工程を含んでいればよく、ここで、より好ましくは、前記界面活性剤成分と、前記オイルと、前記難水溶性機能性成分との混合は、前記オイルに対する前記界面活性剤成分の重量比が９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対する前記界面活性剤成分の重量比が５．２０以上２００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、前記難水溶性機能性成分に対する前記オイルの重量比（オイル／難水溶性機能性成分）が、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、前記難水溶性機能性成分に対する前記オイルの重量比（オイル／難水溶性機能性成分）が、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下であるように行う。 The method for producing the composition for preparing a microemulsion according to one embodiment of the present invention may include a mixing step of mixing the surfactant component, the oil, and the poorly water-soluble functional component, Here, more preferably, in the mixing of the surfactant component, the oil, and the poorly water-soluble functional component, the weight ratio of the surfactant component to the oil is 9.20 or more and 240 or less. When the weight ratio of the surfactant component to the total weight of the oil and the poorly water-soluble functional component is 5.20 or more and 200 or less, and the LogP of the poorly water-soluble functional component is 4.2 or more. The weight ratio of the oil to the poorly water-soluble functional component (oil / poorly water-soluble functional component) is [−0.38 × (LogP of the poorly water-soluble functional component) +5.169] or more and 2000 or less. Yes When LogP of the poorly water-soluble functional component is less than 4.2, the weight ratio of the oil to the poorly water-soluble functional component (oil / poorly water-soluble functional component) is [−4.955 × ( It is carried out so as to be not less than 2000 and not more than the poorly water-soluble functional component (LogP) +23.56].
前記混合工程において、前記界面活性剤成分と、前記オイルと、前記難水溶性機能性成分とを混合する順序は特に限定されるものではなく、すべてを同時に混合してもよいし、前記界面活性剤成分と前記オイルとを混合した後に前記難水溶性機能性成分を混合してもよいし、前記界面活性剤成分と前記難水溶性機能性成分とを混合した後に前記オイルを混合してもよいし、前記オイルと前記難水溶性機能性成分とを混合した後に前記界面活性剤成分を混合してもよい。 In the mixing step, the order in which the surfactant component, the oil, and the poorly water-soluble functional component are mixed is not particularly limited, and all may be mixed simultaneously, or the surfactant may be mixed. The poorly water-soluble functional component may be mixed after mixing the agent component and the oil, or the oil may be mixed after mixing the surfactant component and the poorly water-soluble functional component. Alternatively, the surfactant component may be mixed after mixing the oil and the poorly water-soluble functional component.
前記各成分を混合する方法は、前記界面活性剤成分と、前記オイルと、前記難水溶性機能性成分とを均一に溶解させることができる方法であれば特に限定されるものではない。例えば、各成分を混合して撹拌する方法を挙げることができる。本発明においては、特に強いせん断力をかけなくとも、各成分を均一に溶解することができる。例えば、マグネティックスターラーを用いて撹拌することにより、各成分を均一に溶解することができる。 The method of mixing the components is not particularly limited as long as the method can uniformly dissolve the surfactant component, the oil, and the poorly water-soluble functional component. For example, there can be mentioned a method of mixing and stirring each component. In the present invention, each component can be uniformly dissolved without applying a particularly strong shearing force. For example, each component can be uniformly dissolved by stirring using a magnetic stirrer.
また、各成分を混合するときの温度も特に限定されるものではないが、液温が、２０℃以上９０℃以下であることがより好ましく、３０℃以上７５℃以下であることがさらに好ましい。 The temperature at which the components are mixed is not particularly limited, but the liquid temperature is more preferably 20 ° C or more and 90 ° C or less, and even more preferably 30 ° C or more and 75 ° C or less.
〔４．マイクロエマルションの製造方法〕
本発明の一実施形態に係るマイクロエマルションの製造方法は、ポリソルベート８０及びポリオキシエチレンヒマシ油から選択される少なくともいずれかを含む界面活性剤成分と、前記オイルと、前記難水溶性機能性成分とを混合する混合工程と、前記混合工程により得られた組成物と、水性媒体とを混合する水性媒体添加工程とを含んでいればよい。
[4. Production method of microemulsion)
The method for producing a microemulsion according to one embodiment of the present invention includes a surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil, the oil, and the poorly water-soluble functional component. And an aqueous medium adding step of mixing the composition obtained in the mixing step with an aqueous medium.
前記混合工程は上記〔３．マイクロエマルション調製用組成物の製造方法〕にて説明したとおりである。 The mixing step is as described in [3. Production method of composition for preparing microemulsion].
前記混合工程により得られた組成物と、水性媒体とを混合する工程は、前記混合工程により得られた組成物に、前記水性媒体を添加する工程である。本工程において、前記水性媒体は、一度に全量を加えてもよく、数回に分けて撹拌しながら加えてもよい。 The step of mixing the composition obtained in the mixing step with an aqueous medium is a step of adding the aqueous medium to the composition obtained in the mixing step. In this step, the aqueous medium may be added in its entirety at once, or may be added several times with stirring.
前記混合工程により得られた組成物と前記水性媒体を混合する方法は、前記水性媒体中に前記組成物を乳化粒子として分散させることができる方法であれば特に限定されるものではない。例えば、前記組成物と前記水性媒体とを混合して撹拌する方法を挙げることができる。本工程においても、特に強いせん断力をかけなくとも、前記組成物を乳化粒子として前記水性媒体中に分散させることができる。例えば、マグネティックスターラーを用いて撹拌することができる。 The method of mixing the composition obtained in the mixing step with the aqueous medium is not particularly limited as long as the composition can be dispersed as emulsified particles in the aqueous medium. For example, there can be mentioned a method of mixing and stirring the composition and the aqueous medium. Also in this step, the composition can be dispersed in the aqueous medium as emulsified particles without applying a particularly strong shearing force. For example, stirring can be performed using a magnetic stirrer.
また、前記組成物と前記水性媒体とを混合するときの温度も特に限定されるものではないが、液温が、２０℃以上９０℃以下であることがより好ましく、３０℃以上７５℃以下であることがさらに好ましい。 The temperature at which the composition is mixed with the aqueous medium is not particularly limited, but the liquid temperature is more preferably 20 ° C or more and 90 ° C or less, and is preferably 30 ° C or more and 75 ° C or less. It is more preferred that there be.
〔４．マイクロエマルションの利用〕
本発明には、本発明の一実施形態に係るマイクロエマルションを含む、医薬品、機能性食品、化粧品、コーティング剤、又は、殺虫剤も含まれる。
[4. Use of microemulsion)
The present invention also includes a pharmaceutical, a functional food, a cosmetic, a coating agent, or an insecticide containing the microemulsion according to one embodiment of the present invention.
本発明は上述した各実施形態に限定されるものではなく、請求項に示した範囲で種々の変更が可能であり、異なる実施形態にそれぞれ開示された技術的手段を適宜組み合わせて得られる実施形態についても本発明の技術的範囲に含まれる。 The present invention is not limited to the embodiments described above, and various modifications are possible within the scope shown in the claims, and embodiments obtained by appropriately combining technical means disclosed in different embodiments. Is also included in the technical scope of the present invention.
以下に、本発明を実施例により具体的に説明するが、本発明はこれら実施例に限定されるものではない。 Hereinafter, the present invention will be described specifically with reference to Examples, but the present invention is not limited to these Examples.
〔評価方法〕
実施例及び比較例で得られたマイクロエマルションは以下の方法により評価した。
〔Evaluation method〕
The microemulsions obtained in Examples and Comparative Examples were evaluated by the following methods.
（マイクロエマルション中の乳化粒子の平均粒子径、ＰＤＩ（Polydispersity Index：多分散度）、粒子径分布（サブピークの有無）の測定）
実施例及び比較例で得られたマイクロエマルションをイオン交換水で２０倍に希釈して、測定用のサンプルを調製した。Ｚｅｔａｓｉｚｅｒ Ｎａｎｏ ＺＳ（マルバーン・パナリティカル社製)を用いて、測定モード“size-small-vol-cell×1.SOP”にて、ＰＤＩを測定した。さらに、Z-average値に基づいて、乳化粒子の粒子径を測定した。同じサンプルを用いて３回測定を行い、その平均値を、乳化粒子の平均粒子径とした。
(Measurement of average particle size of emulsified particles in microemulsion, PDI (Polydispersity Index: polydispersity), particle size distribution (presence or absence of sub-peak))
The microemulsions obtained in Examples and Comparative Examples were diluted 20 times with ion-exchanged water to prepare samples for measurement. PDI was measured using Zetasizer Nano ZS (manufactured by Malvern Panalytical Co.) in the measurement mode “size-small-vol-cell × 1.SOP”. Further, the particle size of the emulsified particles was measured based on the Z-average value. The measurement was performed three times using the same sample, and the average value was defined as the average particle size of the emulsified particles.
前記測定結果として得られた粒度分布図からサブピークの有無を判断した。なおサブピークがあるときはPeak-2、Peak-3等として自動的に測定結果が出力される。 The presence or absence of a subpeak was determined from the particle size distribution diagram obtained as a result of the measurement. When there is a sub-peak, the measurement result is automatically output as Peak-2, Peak-3, or the like.
（透明度）
実施例及び比較例で得られたマイクロエマルションを目視により観察し、均一かつ澄明である場合を「透明」、液層の二層分離や析出物が浮遊している場合を「曇り有」とした。
(Transparency)
The microemulsions obtained in Examples and Comparative Examples were visually observed, and the case where uniform and clear was “transparent”, and the case where two-layer separation of the liquid layer and the precipitate were floating were “cloudy”. .
（安定性／沈殿発生）
実施例及び比較例で得られたマイクロエマルションを無色透明なガラス瓶に密閉し、温度２５℃の条件化にて、静置し、静置開始時から沈殿が生じたときまでの時間を測定した。
(Stability / settling)
The microemulsions obtained in Examples and Comparative Examples were sealed in colorless and transparent glass bottles, allowed to stand at a temperature of 25 ° C., and the time from the start of standing to when precipitation occurred was measured.
〔マイクロエマルション調製用組成物及びマイクロエマルションの調製〕
（実施例１）
１０ｍｌのビーカーに、難水溶性機能性成分としてＣｏＱ１０（富士フイルム和光純薬社製、ユビキノン−１０）、オイルとして大豆油（富士フイルム和光純薬社製、大豆油）、及びポリソルベート８０（花王社製、エマゾールＯ−１２０Ｖ）を、表１に記載の重量比となるように秤量した。秤量したビーカー内の混合物を、マグネティックスターラーを用いて、６０℃で、磁力攪拌子によって、難水溶性機能性成分が全て均一に溶解するまで攪拌し、粘性のある液体であるマイクロエマルション調製用組成物を得た。このマイクロエマルション調製用組成物に、表１に記載の重量比となるように、イオン交換水を加え、６０℃で、さらに１〜３分間、攪拌し、不均一な溶け残りやダマが無いことを目視で確認した後、氷水槽で室温まで冷却して、マイクロエマルションを得た。得られたマイクロエマルションの透明度、安定性、並びに、マイクロエマルション中の乳化粒子の平均粒子径、ＰＤＩ及びサブピークの有無を評価した。結果を表１に示す。
(Preparation of microemulsion preparation composition and microemulsion)
(Example 1)
In a 10 ml beaker, CoQ10 (Fujifilm Wako Pure Chemical, Ubiquinone-10) as a poorly water-soluble functional ingredient, soybean oil (Fujifilm Wako Pure Chemical, soybean oil) as oil, and Polysorbate 80 (Kaosha) And Emazole O-120V) were weighed so as to have the weight ratios shown in Table 1. The weighed mixture in the beaker is stirred with a magnetic stirrer at 60 ° C. using a magnetic stirrer until all the poorly water-soluble functional components are uniformly dissolved, and the composition for preparing a microemulsion is a viscous liquid. I got something. To the composition for preparing microemulsion, add ion-exchanged water so as to have a weight ratio shown in Table 1, and further stir at 60 ° C. for 1 to 3 minutes, so that there is no non-uniform undissolved residue or lumps. Was visually observed, and then cooled to room temperature in an ice water bath to obtain a microemulsion. The transparency and stability of the obtained microemulsion, and the average particle size of the emulsified particles in the microemulsion, the presence of PDI and the presence of subpeaks were evaluated. Table 1 shows the results.
（実施例２〜１２）
ＣｏＱ１０、大豆油、ポリソルベート８０、及びイオン交換水の重量比を、表１に記載の重量比に変更した以外は、実施例１と同様にして、マイクロエマルションを調製した。得られたマイクロエマルションを評価した。結果を表１に示す。
(Examples 2 to 12)
A microemulsion was prepared in the same manner as in Example 1, except that the weight ratio of CoQ10, soybean oil, polysorbate 80, and ion-exchanged water was changed to the weight ratio shown in Table 1. The obtained microemulsion was evaluated. Table 1 shows the results.
（比較例１〜１０）
ＣｏＱ１０、大豆油、ポリソルベート８０、及びイオン交換水の重量比を、表２に記載の重量比に変更した以外は、実施例１と同様にして、マイクロエマルションを調製した。得られたマイクロエマルションを評価した。結果を表２に示す。
(Comparative Examples 1 to 10)
A microemulsion was prepared in the same manner as in Example 1 except that the weight ratio of CoQ10, soybean oil, polysorbate 80, and ion-exchanged water was changed to the weight ratio shown in Table 2. The obtained microemulsion was evaluated. Table 2 shows the results.
（実施例１３〜１６、比較例１１及び１２）
オイルとして、表３に示すオイルを用い、ＣｏＱ１０、オイル、ポリソルベート８０、及びイオン交換水の重量比を、表３に記載の重量比に変更した以外は、実施例１と同様にして、マイクロエマルションを調製した。得られたマイクロエマルションを以下の方法により評価した。結果を表３に示す。
(Examples 13 to 16, Comparative Examples 11 and 12)
A microemulsion was prepared in the same manner as in Example 1 except that the oil shown in Table 3 was used as the oil, and the weight ratio of CoQ10, oil, polysorbate 80, and ion-exchanged water was changed to the weight ratio shown in Table 3. Was prepared. The obtained microemulsion was evaluated by the following method. Table 3 shows the results.
実施例１３〜１６及び比較例１１及び１２では、オイルとして以下のオイルを使用した。
ヤシ油（富士フイルム和光純薬社製、ヤシ油）
ベルガモット油（富士フイルム和光純薬社製、ベルガモット油）
ローズヒップ油（富士フイルム和光純薬社製、ローズヒップ油）
アーモンド油（富士フイルム和光純薬社製、アーモンド油）
In Examples 13 to 16 and Comparative Examples 11 and 12, the following oils were used as oils.
Coconut oil (coconut oil, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)
Bergamot oil (Fujifilm Wako Pure Chemical Industries, Bergamot oil)
Rosehip oil (Rosehip oil, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)
Almond oil (Almond oil, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)
（実施例１７〜３８）
難水溶性機能性成分として表４〜１２に示す難水溶性機能性成分を用い、難水溶性機能性成分、大豆油、ポリソルベート８０、及びイオン交換水の重量比を、各表に記載の重量比に変更した以外は、実施例１と同様にして、マイクロエマルションを調製した。得られたマイクロエマルションを評価した。結果を表４〜１２に示す。
(Examples 17 to 38)
The sparingly water-soluble functional components shown in Tables 4 to 12 were used as the sparingly water-soluble functional components, and the weight ratios of the sparingly water-soluble functional components, soybean oil, polysorbate 80, and ion-exchanged water were shown in the respective tables A microemulsion was prepared in the same manner as in Example 1 except that the ratio was changed. The obtained microemulsion was evaluated. The results are shown in Tables 4 to 12.
実施例１７〜３８では、難水溶性機能性成分として以下の難水溶性機能性成分を使用した。
クルクミン（東京化成工業社製、クルクミン）(重量％）
シクロスポリンＡ（東京化成工業社製、シクロスポリンＡ）
ＤＤＴ（東京化成工業社製、ＤＤＴ）
テストステロン（東京化成工業社製、テストステロン）
パクリタキセル（東京化成工業社製、パクリタキセル）
メントール（東京化成工業社製、（−）−メントール）
トコフェロール（東京化成工業社製、ＤＬ−α−トコフェロール）
トコトリエノール（オリザ油化社製、オリザトコトリエノール−９０）
インドメタシン（東京化成工業社製、インドメタシン）
In Examples 17 to 38, the following poorly water-soluble functional components were used as the poorly water-soluble functional components.
Curcumin (Curcumin, manufactured by Tokyo Chemical Industry Co., Ltd.) (% by weight)
Cyclosporin A (Tokyo Kasei Kogyo KK, Cyclosporin A)
DDT (DDT made by Tokyo Chemical Industry Co., Ltd.)
Testosterone (Tokyo Chemical Industry, Testosterone)
Paclitaxel (Tokyo Kasei Kogyo, Paclitaxel)
Menthol (manufactured by Tokyo Chemical Industry Co., Ltd., (-)-menthol)
Tocopherol (manufactured by Tokyo Chemical Industry Co., Ltd., DL-α-tocopherol)
Tocotrienol (Orizatocotrienol-90, manufactured by Oriza Yuka Co., Ltd.)
Indomethacin (Tokyo Kasei Kogyo Co., Ltd., Indomethacin)
表１〜１２に示されるように、前記オイルに対する前記ポリソルベート８０の重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対するポリソルベート８０の重量比が、５．２０以上２００以下である場合には、得られるマイクロエマルションの乳化粒子の平均粒子径が１８ｎｍ以下で、ＰＤＩ（粒度分布指標）が０．１４以下で、１００ｎｍ以上の粒子（サブピーク）を含まない単一分散の難水溶性薬物を包含するマイクロエマルションを得ることができることが分かる。 As shown in Tables 1 to 12, the weight ratio of the polysorbate 80 to the oil is 9.20 to 240, and the weight ratio of the polysorbate 80 to the total weight of the oil and the poorly water-soluble functional component is When the average particle size of the emulsified particles of the obtained microemulsion is 18 nm or less, the PDI (particle size distribution index) is 0.14 or less, and the particles (subpeaks) of 100 nm or more It can be seen that a microemulsion containing a monodisperse poorly water-soluble drug that does not contain can be obtained.
また、表２〜３より、前記オイルに対する前記ポリソルベート８０の重量比が９．２０を下まわり、４に近づくにつれて、平均粒子径は増大する傾向があることが分かる。 Also, from Tables 2 and 3, it can be seen that as the weight ratio of the polysorbate 80 to the oil falls below 9.20 and approaches 4, the average particle size tends to increase.
また、表１〜１２に示されるように、前記オイルに対する前記ポリソルベート８０の重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対するポリソルベート８０の重量比が、５．２０以上２００以下であり、前記難水溶性機能性成分に対する前記オイルの重量比が、前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である場合には、得られるマイクロエマルションの乳化粒子の平均粒子径が１８ｎｍ以下で、ＰＤＩ（粒度分布指標）が０．１４以下で、１００ｎｍ以上の粒子（サブピーク）を含まない単一分散の難水溶性薬物を包含する安定なマイクロエマルションを得ることができることが分かる。 Further, as shown in Tables 1 to 12, the weight ratio of the polysorbate 80 to the oil is 9.20 or more and 240 or less, and the weight of the polysorbate 80 with respect to the total weight of the oil and the poorly water-soluble functional component. When the ratio is from 5.20 to 200 and the weight ratio of the oil to the poorly water-soluble functional component is LogP of the poorly water-soluble functional component is 4.2 or more, [-0.38 × (LogP of poorly water-soluble functional component) +5.169] or more and 2,000 or less, and when LogP of the poorly water-soluble functional component is less than 4.2, [−4.955 × (poorly water-soluble functional component)] When the average particle size of the emulsified particles of the obtained microemulsion is 18 nm or less, the PDI (particle size distribution index) is 0.14 or less. In the following, it can be seen that a stable microemulsion containing a monodisperse poorly water-soluble drug that does not contain particles (subpeak) of 100 nm or more can be obtained.
即ち、前記難水溶性機能性成分に対する前記オイルの重量比が、前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である場合には、前記難水溶性機能性成分に対する前記オイルの重量比が、前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］未満である実施例１２、２６及び３８、並びに、前記難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］未満である実施例２３、２８、及び２９と比較して、薬物の析出が起こらず、安定性の面でより優れることがわかる。 That is, when the weight ratio of the oil to the poorly water-soluble functional component is LogP of the poorly water-soluble functional component of 4.2 or more, [−0.38 × (LogP of the poorly water-soluble functional component) ) +5.169] or more and 2000 or less, and when the LogP of the poorly water-soluble functional component is less than 4.2, [−4.955 × (LogP of the poorly water-soluble functional component) +23.56] or more When it is 2,000 or less, the weight ratio of the oil to the poorly water-soluble functional component is [−0.38 × (poorly water-soluble) when the LogP of the poorly water-soluble functional component is 4.2 or more. (LogP of the sexually functional component) +5.169], and when the LogP of the poorly water-soluble functional component is less than 4.2, [−4.955 × (difficult Water-soluble functional component LogP) +2 .56] below in an exemplary 23 and 28, and compared with 29, does not occur drug deposition, it can be seen that more excellent in terms of stability.
（実施例３９及び４０）
難水溶性機能性成分として表１３に示す複数の難水溶性機能性成分を、オイルとして表１３に記載のオイルを用い、難水溶性機能性成分、オイル、ポリソルベート８０、及びイオン交換水の重量比を、表１３に記載の重量比に変更した以外は、実施例１と同様にして、マイクロエマルションを調製した。得られたマイクロエマルションを評価した。結果を表１３に示す。実施例４０では、オイルとして以下のオイルを使用した。
スクワラン（オリザ油化社製、オリザスクワラン）
(Examples 39 and 40)
Using a plurality of poorly water-soluble functional components shown in Table 13 as poorly water-soluble functional components and oils shown in Table 13 as oils, weights of poorly water-soluble functional components, oil, polysorbate 80, and ion-exchanged water A microemulsion was prepared in the same manner as in Example 1 except that the ratio was changed to the weight ratio shown in Table 13. The obtained microemulsion was evaluated. Table 13 shows the results. In Example 40, the following oil was used as the oil.
Squalane (Oriza Squalane, manufactured by Oriza Yuka Co., Ltd.)
表１３に示されるように、実施例３９及び４０では３種類の難水溶性機能性成分を併用した。難水溶性機能性成分の種類（ＬｏｇＰ値）によって必要となるオイルの量が異なるため、使用したオイルの量（２．５０重量％）をそれぞれの難水溶性機能性成分に振り分けた量を、難水溶性機能性成分に対するオイルの重量比の計算に用いた。表１３に示されるように、複数種類の難水溶性機能性成分を併用する場合にも、前記オイルに対する前記ポリソルベート８０の重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対するポリソルベート８０の重量比が、５．２０以上２００以下であり、それぞれの難水溶性機能性成分に対する前記オイルの重量比が、前記難水溶性機能性成分のＬｏｇＰが４．２以上であるとき、［−０．３８×（難水溶性機能性成分のＬｏｇＰ）＋５．１６９］以上２０００以下であり、それぞれの難水溶性機能性成分のＬｏｇＰが４．２未満であるとき、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である場合には、得られるマイクロエマルションの乳化粒子の平均粒子径が１８ｎｍ以下で、ＰＤＩ（粒度分布指標）が０．１４以下で、１００ｎｍ以上の粒子（サブピーク）を含まない単一分散の難水溶性薬物を包含する安定なマイクロエマルションを得ることができることが分かる。 As shown in Table 13, in Examples 39 and 40, three types of poorly water-soluble functional components were used in combination. Since the amount of oil required varies depending on the type (Log P value) of the poorly water-soluble functional component, the amount of the used oil (2.50% by weight) divided into the respective poorly water-soluble functional components is It was used to calculate the weight ratio of the oil to the poorly water-soluble functional component. As shown in Table 13, even when a plurality of types of poorly water-soluble functional components are used in combination, the weight ratio of the polysorbate 80 to the oil is 9.20 or more and 240 or less, and The weight ratio of polysorbate 80 to the total weight of the functional component is 5.20 or more and 200 or less, and the weight ratio of the oil to each poorly water-soluble functional component is LogP of the poorly water-soluble functional component. When it is 4.2 or more, it is [−0.38 × (LogP of poorly water-soluble functional component) +5.169] or more and 2000 or less, and LogP of each poorly water-soluble functional component is less than 4.2. In some cases, when it is not less than [−4.955 × (LogP of poorly water-soluble functional component) +23.56] and not more than 2000, the average particle size of the emulsified particles of the obtained microemulsion It can be seen that a stable microemulsion containing a monodisperse poorly water-soluble drug having a particle size distribution index (PDI) of 0.14 or less and containing no particles (subpeak) of 100 nm or more can be obtained. .
（実施例４１〜４６）
難水溶性機能性成分としてクルクミンを、オイルとして大豆油又は中鎖脂肪酸トリグリセリドを用い、界面活性剤成分としてポリオキシエチレンヒマシ油を単独又はポリソルベート８０との併用で用い、難水溶性機能性成分、オイル、界面活性剤成分、及びイオン交換水の重量比を、表１４に記載の重量比に変更した以外は、実施例１と同様にして、マイクロエマルションを調製した。得られたマイクロエマルションを評価した。結果を表１４に示す。実施例４１では、界面活性剤成分として、ポリオキシエチレンヒマシ油を単独で使用した。実施例４２〜４６では、界面活性剤成分として、ポリオキシエチレンヒマシ油とポリソルベート８０とを併用した。また、実施例４５及び４６では、オイルとして中鎖脂肪酸トリグリセリドを使用した。オイルとして以下のオイル、及び界面活性剤として以下の界面活性剤を使用した。
中鎖脂肪酸トリグリセリド（花王社製、商品名：ココナードＲＫ）
ポリオキシエチレンヒマシ油（ＢＡＳＦ社製、Kolliphor（登録商標）EL）
(Examples 41 to 46)
Curcumin as a poorly water-soluble functional component, using soybean oil or medium-chain fatty acid triglyceride as an oil, using a polyoxyethylene castor oil alone or in combination with polysorbate 80 as a surfactant component, a poorly water-soluble functional component, A microemulsion was prepared in the same manner as in Example 1, except that the weight ratio of the oil, the surfactant component, and the ion-exchanged water was changed to the weight ratio shown in Table 14. The obtained microemulsion was evaluated. Table 14 shows the results. In Example 41, polyoxyethylene castor oil was used alone as a surfactant component. In Examples 42 to 46, polyoxyethylene castor oil and polysorbate 80 were used in combination as surfactant components. In Examples 45 and 46, medium chain fatty acid triglyceride was used as the oil. The following oil was used as the oil, and the following surfactant was used as the surfactant.
Medium-chain fatty acid triglyceride (Kao Corporation, trade name: Coconard RK)
Polyoxyethylene castor oil (Kolliphor (registered trademark) EL, manufactured by BASF)
表１４に示されるように、前記ポリオキシエチレンヒマシ油の前記オイルに対する重量比又は前記ポリソルベート８０及びポリオキシエチレンヒマシ油の両方で構成される界面活性剤成分の前記オイルに対する重量比が、９．２０以上２４０以下であり、前記オイルと難水溶性機能性成分との合計重量に対する前記ポリオキシエチレンヒマシ油の重量比又は前記オイルと難水溶性機能性成分との合計重量に対する前記ポリソルベート８０及びポリオキシエチレンヒマシ油の両方で構成される界面活性剤成分の重量比が、５．２０以上２００以下であり、前記難水溶性機能性成分に対する前記オイルの重量比が、［−４．９５５×（難水溶性機能性成分のＬｏｇＰ）＋２３．５６］以上２０００以下である場合には、得られるマイクロエマルションの乳化粒子の平均粒子径が１８ｎｍ以下で、ＰＤＩ（粒度分布指標）が０．１４以下で、１００ｎｍ以上の粒子（サブピーク）を含まない単一分散の難水溶性薬物を包含する安定なマイクロエマルションを得ることができることが分かる。 As shown in Table 14, the weight ratio of the polyoxyethylene castor oil to the oil or the weight ratio of the surfactant component composed of both the polysorbate 80 and the polyoxyethylene castor oil to the oil was 9. 20 or more and 240 or less, and the weight ratio of the polyoxyethylene castor oil to the total weight of the oil and the poorly water-soluble functional component or the polysorbate 80 and the polysorbate 80 to the total weight of the oil and the poorly water-soluble functional component The weight ratio of the surfactant component composed of both oxyethylene castor oil is 5.20 or more and 200 or less, and the weight ratio of the oil to the poorly water-soluble functional component is [−4.955 × ( When the water-insoluble functional component (LogP) +23.56] or more and 2000 or less, the resulting microemulsion A stable micro-particle containing a monodisperse poorly water-soluble drug having an average particle size of emulsified particles of 18 nm or less, a PDI (particle size distribution index) of 0.14 or less, and containing no particles (sub-peak) of 100 nm or more. It can be seen that an emulsion can be obtained.
本発明の一実施形態に係るマイクロエマルションを調製するための組成物及びマイクロエマルションは、上述した構成を備えることにより、乳化粒子の粒子径が小さく、粒子径分布が狭く、且つ、粒子径の均質性が向上しているとともに、安定性に優れたマイクロエマルションを提供することができる。それゆえ、かかるマイクロエマルションを用いた、医薬品、サプリメント等の機能性食品、化粧品、コーティング剤等の分野で利用することができる。 The composition and the microemulsion for preparing the microemulsion according to one embodiment of the present invention are provided with the above-described configuration, so that the particle size of the emulsified particles is small, the particle size distribution is narrow, and the particle size is uniform. A microemulsion having improved stability and excellent stability can be provided. Therefore, the microemulsion can be used in the fields of functional foods such as pharmaceuticals and supplements, cosmetics, coating agents and the like using the microemulsion.
Claims (3)
前記オイルに対する、前記ポリソルベート８０及び前記ポリオキシエチレンヒマシ油から選択される少なくともいずれかのみで構成される前記界面活性剤成分の重量比が、９．２０以上２４０以下であり、
前記オイルと難水溶性機能性成分との合計重量に対する、前記ポリソルベート８０及び前記ポリオキシエチレンヒマシ油から選択される少なくともいずれかのみで構成される前記界面活性剤成分の重量比が、５．２０以上２００以下である、請求項１に記載のマイクロエマルション。 A surfactant component containing at least one selected from polysorbate 80 and polyoxyethylene castor oil, an oil, a composition containing a poorly water-soluble functional component, and an aqueous medium ,
For the previous SL oil, the weight ratio of the polysorbate 80 and the surfactant component consisting only of at least one selected from the polyoxyethylene castor oil is at 240 or less than 9.20,
The weight ratio of the surfactant component composed of at least one selected from the polysorbate 80 and the polyoxyethylene castor oil to the total weight of the oil and the poorly water-soluble functional component is 5.20. The microemulsion according to claim 1, which is at least 200 and no more than 200.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019194591A JP6667043B1 (en) | 2019-10-25 | 2019-10-25 | Microemulsions and the use of microemulsions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019194591A JP6667043B1 (en) | 2019-10-25 | 2019-10-25 | Microemulsions and the use of microemulsions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539307A Division JP6622950B1 (en) | 2019-07-08 | 2019-07-08 | Compositions for preparing microemulsions, microemulsions, methods for their production and use of microemulsions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP6667043B1 true JP6667043B1 (en) | 2020-03-18 |
| JP2021011467A JP2021011467A (en) | 2021-02-04 |
Family
ID=70000588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019194591A Active JP6667043B1 (en) | 2019-10-25 | 2019-10-25 | Microemulsions and the use of microemulsions |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6667043B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113908082A (en) * | 2021-10-14 | 2022-01-11 | 上海应用技术大学 | Preparation method of soybean oil microemulsion capable of being infinitely diluted |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2815689C (en) * | 2010-11-11 | 2016-11-22 | Abbvie Biotechnology Ltd. | Improved high concentration anti-tnf.alpha. antibody liquid formulations |
-
2019
- 2019-10-25 JP JP2019194591A patent/JP6667043B1/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113908082A (en) * | 2021-10-14 | 2022-01-11 | 上海应用技术大学 | Preparation method of soybean oil microemulsion capable of being infinitely diluted |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021011467A (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choi et al. | Nanoemulsions as delivery systems for lipophilic nutraceuticals: Strategies for improving their formulation, stability, functionality and bioavailability | |
| Öztürk | Nanoemulsions for food fortification with lipophilic vitamins: Production challenges, stability, and bioavailability | |
| Gulotta et al. | Nanoemulsion-based delivery systems for polyunsaturated (ω-3) oils: formation using a spontaneous emulsification method | |
| AU2008329540B2 (en) | Nanoemulsions | |
| CN103037708B (en) | Nanoemulsion including sucrose fatty acid ester | |
| Li et al. | Nanoemulsion-based delivery approaches for nutraceuticals: Fabrication, application, characterization, biological fate, potential toxicity and future trends | |
| EP0866117A1 (en) | Microemulsion | |
| CA2962900C (en) | Non-synthetic emulsion-based lipid formulations and methods of use | |
| CN107080734A (en) | The emulsion of PEG derivatives comprising tocopherol | |
| JP2009505809A (en) | Emulsifier system, its emulsion and its use | |
| Lacatusu et al. | Lipid nanocarriers based on natural compounds: An evolving role in plant extract delivery | |
| TWI531318B (en) | Microemulsion preconcentrates and microemulsions, and preparation processes of the same | |
| CN107259506A (en) | A kind of preparation technology of bata-carotene nanosized emulsion and application | |
| Barradas et al. | Nanoemulsions as optimized vehicles for essential oils | |
| Li et al. | Preparation of α-linolenic-acid-loaded water-in-oil-in-water microemulsion and its potential as a fluorescent delivery carrier with a free label | |
| JP6667043B1 (en) | Microemulsions and the use of microemulsions | |
| JP6622950B1 (en) | Compositions for preparing microemulsions, microemulsions, methods for their production and use of microemulsions | |
| JP2018177751A (en) | Oil-in-water emulsion composition, skin external preparation, and skin external preparation production method | |
| US20100196456A1 (en) | Emulsion preconcentrates and micellar formulations containing wood resins | |
| Garti et al. | Improved solubilization and bioavailability of nutraceuticals in nanosized self‐assembled liquid vehicles | |
| WO2023177313A1 (en) | A composition forming stable monodisperse emulsions in water | |
| WO2023139907A1 (en) | Nanoemulsion endowed with antiseptic effect | |
| CN111346087B (en) | Oily composition containing vitamin E | |
| Kalladathvalappil Venugopalan et al. | Enhancement of oxidative stability of polyunsaturated fatty acid‐rich fish oil: microencapsulation using chitosan‐whey protein complex and betalain | |
| JP2020083806A (en) | Vitamin E-containing oily composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191105 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20191105 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20191114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6667043 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |